Dextromethorphan Dosing
For adults and children ≥12 years: 10-30 mg every 4-6 hours (maximum 120 mg/24 hours); for children 6-11 years: 5-15 mg every 4-6 hours; for children 4-5 years: 2.5-7.5 mg every 4-6 hours; do not use in children under 4 years. 1
Adult Dosing
The FDA-approved dosing for immediate-release dextromethorphan in adults is:
- Standard dose: 10-15 mg every 4-6 hours (tid or qid)
- Maximum single dose: 30 mg
- Maximum daily dose: 120 mg/24 hours 2, 1
For extended-release formulations (dextromethorphan polistirex):
- Adults and children ≥12 years: 10 mL (equivalent to 60 mg dextromethorphan hydrobromide) every 12 hours
- Maximum: 20 mL in 24 hours 1
Pediatric Dosing
Immediate-release formulations:
- Ages 12+ years: 10-15 mg every 4-6 hours (same as adults)
- Ages 6-11 years: 5-15 mg every 4-6 hours 3, 1
- Ages 4-5 years: 2.5-7.5 mg every 4-6 hours 1
- Under 4 years: Do not use 1
Extended-release formulations:
- Ages 12+ years: 10 mL every 12 hours (maximum 20 mL/24 hours)
- Ages 6-11 years: 5 mL every 12 hours (maximum 10 mL/24 hours)
- Ages 4-5 years: 2.5 mL every 12 hours (maximum 5 mL/24 hours)
- Under 4 years: Do not use 1
Weight-Based Dosing Considerations
Research suggests that age-based dosing results in substantial variability in relative drug exposure (0.35-0.94 mg/kg per dose). A dose of approximately 0.5 mg/kg may optimize symptomatic relief while minimizing adverse events in children, though this is not yet standard practice 4. The pharmacokinetic study in children demonstrated that doses ranging from 7.5-30 mg (based on age-weight schedules) were safe and well-tolerated 5.
Critical Clinical Caveats
Limited Efficacy Evidence
The evidence supporting dextromethorphan's antitussive efficacy is weak, particularly for acute cough. Multiple studies show minimal to no benefit over placebo for cough associated with upper respiratory infections 3, 6, 7. One study found no difference in cough frequency, severity, or sound pressure between 30 mg dextromethorphan and placebo in adults with acute cough 7.
Pediatric Safety Concerns
Over-the-counter cough medications containing dextromethorphan should not be routinely prescribed to children until proven effective in randomized controlled trials 8. These preparations are associated with adverse events, including reported deaths from toxicity in young children 8. The FDA and manufacturers have labeled these products "do not use in children under 4 years of age."
Specific Recommendations by Clinical Context
For acute bronchitis:
- Antitussive agents (including dextromethorphan) are occasionally useful for short-term symptomatic relief
- Quality of evidence: fair; benefit: small/weak; Grade C recommendation 3
For chronic cough in children:
- OTC cough medications have little, if any, benefit
- Use must be balanced against adverse events
- Honey may offer more relief than dextromethorphan for acute cough in children 8
For lung cancer-related cough:
- Dextromethorphan 10-15 mg tid or qid may be tried as initial therapy
- If ineffective, escalate to opioid derivatives (codeine 30-60 mg qid or morphine 5-10 mg) 2
Drug Interactions
When used in combination formulations (e.g., dextromethorphan/bupropion for depression), bupropion inhibits CYP2D6, which metabolizes dextromethorphan to its active metabolite dextrorphan. This reduces abuse potential but requires careful consideration of drug interactions 9, 10.